Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Piedbois

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Pharmacoeconomics|June 17, 2003
Direct treatment costs for patients with lung cancer from first recurrence to death in franceAnne-Chantal Braud, Christine Lévy-Piedbois, Pascal Piedbois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trialThierry Andre, Philippe Colin, Christophe Louvet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1Thierry André, Emmanuel Quinaux, Christophe Louvet, et al.
BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Pharmacoeconomics|June 17, 2003
Direct treatment costs for patients with lung cancer from first recurrence to death in franceAnne-Chantal Braud, Christine Lévy-Piedbois, Pascal Piedbois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trialThierry Andre, Philippe Colin, Christophe Louvet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1Thierry André, Emmanuel Quinaux, Christophe Louvet, et al.
BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.
Pageof 3